- Sareum notes FDA approval of first TYK2 Inhibitor
- Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
- CTA application to MHRA and Corporate Update
- Sareum notes GSK's completed acquisition of Sierra
- Sareum to Present at BioTrinity 2022 Conference
- Sareum notes acquisition of Sierra Oncology by GSK
- Second Price Monitoring Extn
- Price Monitoring Extension
- European Patent Granted for Sareumâ€™s SDC-1802
- SDC-1801: Preclinical Toxicology Report Received
As of last trade,
Sareum Holdings PLC (RYH0:STU) traded at 1.88, 47.34% above the 52 week low of 1.28 set on Mar 11, 2022.
1.28Mar 11 20224.10Oct 19 2021
|Market cap||117.42m GBP|
|EPS (TTM)||-0.0273 |
Data delayed at least 15 minutes, as of Sep 28 2022.